• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·MDLA.JK
Share

Medela Potentia Tbk. Stocks

IDR 182Last Updated 09.11.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

IDR 154.70M

IDR 182
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Medela Potentia Tbk produces and distributes a wide range of pharmaceutical and healthcare products throughout Indonesia and Cambodia. Its offerings include medical devices, spanning from consumable supplies to specialized equipment for hospitals and laboratories. The company also operates the GoApotik.com digital platform, an online channel that makes its products available to retailers, direct consumers, and patients. Founded in 2011, the firm is headquartered in Jakarta Selatan, Indonesia.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, overpriced on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of MDLA.JK is 312 and suggests 71.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.11.2026 05:26

Nebius's Nvidia-backed competitor may postpone its IPO — The Telegraph

11.11.2026 02:45

CoreWeave exceeded Wall Street's expectations. Will this ease concerns about neo-clouds?

11.11.2026 02:17

Stocks fell, and bonds experienced one of their biggest sell-offs: the market is waiting for the Fed to act

11.11.2026 01:51

Money managers seek shelter from AI risks in emerging markets. What are they buying?

11.11.2026 00:09

Boeing books most October aircraft orders in almost three decades

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026